Skip to content

Vasopressin vs. Uterine Artery Clamping for Laparoscopic Cesarean Scar Niche Repair

Noninferiority of Intramyometrial Vasopressin Injection Compared to Bilateral Temporary Clamping of Uterine Arteries During Laparoscopic Excision and Repair of Cesarean Scar Niche

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07446933
Enrollment
30
Registered
2026-03-03
Start date
2024-03-20
Completion date
2026-01-15
Last updated
2026-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section Complications

Brief summary

This study evaluates two methods for controlling intraoperative bleeding during laparoscopic surgery to repair a cesarean scar niche (CSN). It compares the effectiveness of intramyometrial vasopressin injection against bilateral temporary clamping of the uterine arteries using laparoscopic bulldog clips. The goal is to determine if vasopressin injection is non-inferior to arterial clamping in reducing blood loss and maintaining surgical field visibility.

Interventions

Patients receive a local injection of 12 mL of diluted vasopressin into the myometrium directly surrounding the cesarean scar niche. This is performed during the laparoscopic procedure, just before the excision of the fibrous scar tissue, to constrict local blood vessels and minimize intraoperative bleeding.

PROCEDUREBulldog Clamping Group

This intervention involves the temporary mechanical clamping of both uterine arteries using laparoscopic bulldog vascular clips. The clips are applied to block blood flow to the uterus before the niche is excised and are removed once the myometrial reconstruction is complete.

PROCEDUREStandard of Care

Approach: A 3-port laparoscopic approach using Storz endoscopic instruments. Excision: Complete removal of the fibrous scar tissue surrounding the niche defect. Reconstruction: Suturing and repair of the myometrium to resolve the defect.

Sponsors

Zagazig University
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Diagnosis of symptomatic CSN. * Scheduled for laparoscopic excision and repair.

Exclusion criteria

* Contraindications to vasopressin (e.g., severe hypertension or cardiovascular disease). * Presence of other major uterine pathologies (e.g., large myomas or malignancy).

Design outcomes

Primary

MeasureTime frameDescription
Mean Hemoglobin Deficit Mean Hemoglobin Deficit24 hours post-surgery.The difference between preoperative and postoperative hemoglobin concentrations, used as a primary indicator of intraoperative blood loss.

Secondary

MeasureTime frameDescription
Surgical Field Visibility (SFV) ScoreIntraoperativeAssessment of the clarity of the surgical field using Boezaart's scale (0-5), where lower scores indicate better visibility.
Total Operative TimeIntraoperativeDuration of the surgical procedure from the initial incision to the completion of myometrial reconstruction.

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026